4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Recurrent Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Soft Tissue Sarcoma trials Research Report on Recurrent Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Pembrolizumab, Radiation Therapy - Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 27 | 2018-03-28 | 2024-07-23 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
Sarcoma (4) · Ependymoma (3) · Glioma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Lymphoma, Non-Hodgkin (3) · Medulloblastoma (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Rhabdoid Tumor (3) · Rhabdomyosarcoma (3) · Sarcoma, Ewing (3) · Wilms Tumor (3) · Central Nervous System Neoplasms (2)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Histiocytosis (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Kidney Diseases (3) · Kidney Neoplasms (3) · Lung Diseases (3) · Lung Diseases, Interstitial (3)
LY3023414 (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Radiation (1) · Radiotherapy (1) · Specimen Handling (1) · X-Rays (1) · palbociclib (1) · pembrolizumab (1) · tazemetostat (1)
National Cancer Institute (NCI) (3) · Fred Hutchinson Cancer Center (1)
United States (4) · Puerto Rico (3)
Lee Cranmer (1) · Rajen Mody (1) · Susan N Chi (1) · Theodore W Laetsch (1)
U10CA180886 (3)